KR20170113704A - 항-인간 ｃｄ52 면역글루불린 - Google Patents

항-인간 ｃｄ52 면역글루불린 Download PDF

Info

Publication number
KR20170113704A
KR20170113704A KR1020177026871A KR20177026871A KR20170113704A KR 20170113704 A KR20170113704 A KR 20170113704A KR 1020177026871 A KR1020177026871 A KR 1020177026871A KR 20177026871 A KR20177026871 A KR 20177026871A KR 20170113704 A KR20170113704 A KR 20170113704A
Authority
KR
South Korea
Prior art keywords
seq
humanized
cdrs
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177026871A
Other languages
English (en)
Korean (ko)
Inventor
브루스 엘. 로버츠
스리니바스 샨카라
윌리엄 해롤드 브론딕
윌리엄 엠. 사이더스
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170113704(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20170113704A publication Critical patent/KR20170113704A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
KR1020177026871A 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린 Ceased KR20170113704A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17783709P 2009-05-13 2009-05-13
US61/177,837 2009-05-13
PCT/US2010/034704 WO2010132659A2 (en) 2009-05-13 2010-05-13 Anti-human cd52 immunoglobulins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167022759A Division KR20160103160A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린

Publications (1)

Publication Number Publication Date
KR20170113704A true KR20170113704A (ko) 2017-10-12

Family

ID=43085579

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020177026871A Ceased KR20170113704A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린
KR1020167022759A Ceased KR20160103160A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린
KR1020117029662A Expired - Fee Related KR101537840B1 (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린
KR1020157036932A Withdrawn KR20160005143A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린
KR1020147020065A Withdrawn KR20140102764A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020167022759A Ceased KR20160103160A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린
KR1020117029662A Expired - Fee Related KR101537840B1 (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린
KR1020157036932A Withdrawn KR20160005143A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린
KR1020147020065A Withdrawn KR20140102764A (ko) 2009-05-13 2010-05-13 항-인간 ｃｄ52 면역글루불린

Country Status (19)

Country Link
US (5) US8617554B2 (cg-RX-API-DMAC7.html)
EP (3) EP3683317A3 (cg-RX-API-DMAC7.html)
JP (4) JP5894912B2 (cg-RX-API-DMAC7.html)
KR (5) KR20170113704A (cg-RX-API-DMAC7.html)
CN (3) CN102459628A (cg-RX-API-DMAC7.html)
AR (1) AR076770A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010249003B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1013085A2 (cg-RX-API-DMAC7.html)
CA (2) CA2939492C (cg-RX-API-DMAC7.html)
HK (2) HK1222682A1 (cg-RX-API-DMAC7.html)
IL (2) IL216141B (cg-RX-API-DMAC7.html)
MX (1) MX2011012047A (cg-RX-API-DMAC7.html)
MY (1) MY160126A (cg-RX-API-DMAC7.html)
NZ (2) NZ621170A (cg-RX-API-DMAC7.html)
RU (2) RU2016142225A (cg-RX-API-DMAC7.html)
SG (2) SG176060A1 (cg-RX-API-DMAC7.html)
TW (3) TWI529247B (cg-RX-API-DMAC7.html)
WO (1) WO2010132659A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108077B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722184A1 (en) 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
SG176060A1 (en) * 2009-05-13 2011-12-29 Genzyme Corp Anti-human cd52 immunoglobulins
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012144208A1 (ja) 2011-04-18 2012-10-26 国立大学法人東京大学 抗itm2a抗体を用いる癌の診断および治療
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013185165A1 (en) * 2012-06-14 2013-12-19 The Walter And Eliza Hall Institute Of Medical Research Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
US20150299315A1 (en) * 2012-10-22 2015-10-22 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
EP2970496B1 (en) 2013-03-12 2018-07-18 Institute of Arthritis Research LLC Immunologically active polypeptide
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
BR112017026025A2 (pt) 2015-06-03 2018-08-14 Boston Biomedical Inc composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
BR112018072394A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem a tau
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3554515A4 (en) 2016-12-15 2020-08-26 Duke University B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS
CN110546167A (zh) 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
JP2021511068A (ja) * 2017-12-20 2021-05-06 ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｅｎｔｒｉｎ−１に対する抗体、作製方法、及びその使用
CN113544148B (zh) 2018-12-19 2024-04-05 胡默波斯生物医学公司 中和乙型肝炎病毒的抗体和其用途
HRP20231338T1 (hr) 2018-12-20 2024-02-16 Vir Biotechnology, Inc. Kombinirana terapija hbv
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN109929835A (zh) * 2019-03-27 2019-06-25 中国人民解放军第四军医大学 一种鼠单克隆抗体功能轻链可变区基因的扩增方法
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
CA3141457A1 (en) * 2019-07-02 2021-01-07 Michael Paul Wheatcroft Antibodies against caix with reduced affinity for the neonatal fc receptor
TWI800824B (zh) * 2020-05-08 2023-05-01 大陸商亘喜生物科技（上海）有限公司 一種抗cd19抗體的抗體及其製備和應用
IL302786A (en) * 2020-11-19 2023-07-01 Genzyme Corp Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2025031965A1 (en) * 2023-08-04 2025-02-13 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd52 for use in cell therapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0684377B2 (ja) 1986-04-17 1994-10-26 協和醗酵工業株式会社 新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE68909441T2 (de) 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
PT705833E (pt) 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derivado de dc-89
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20050191632A1 (en) 2002-11-01 2005-09-01 John Byrd Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004226492A1 (en) * 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
ES2384105T3 (es) 2003-11-01 2012-06-29 Merck Patent Gmbh Anticuerpo anti-CD52 modificado
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2577405A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
RU2007147414A (ru) * 2005-05-24 2009-07-10 Эйвестаджен Лимитед,In (In) Способ рекомбинантного получения моноклонального антитела к cd52, предназначенного для лечения хронического лимфолейкоза
NZ583636A (en) 2005-05-27 2011-12-22 Biogen Idec Inc Tweak binding antibodies
EP1966244B1 (en) * 2005-12-30 2012-03-21 Merck Patent GmbH Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
CA2649440A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
EP2433649A3 (en) 2006-09-13 2012-10-31 Alcafleu Management GmbH & Co. KG Treatment of multiple sclerosis (MS) with campath-1H
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
JP2010530857A (ja) * 2007-06-22 2010-09-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 神経系障害、特に感染性海綿状脳症及びアルツハイマー病を治療するためのｃｄ５２抗原に対する抗体の使用
SG176060A1 (en) 2009-05-13 2011-12-29 Genzyme Corp Anti-human cd52 immunoglobulins
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
SG10201704269RA (en) 2009-07-15 2017-06-29 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
CN110546167A (zh) 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症

Also Published As

Publication number Publication date
EP3683317A3 (en) 2020-09-30
TW201825115A (zh) 2018-07-16
KR20120111932A (ko) 2012-10-11
IL262639A (en) 2018-12-31
US20200040091A1 (en) 2020-02-06
EP3683317A2 (en) 2020-07-22
RU2603743C2 (ru) 2016-11-27
CN104231084A (zh) 2014-12-24
JP5894912B2 (ja) 2016-03-30
KR101537840B1 (ko) 2015-07-22
SG10201608169QA (en) 2016-11-29
KR20160103160A (ko) 2016-08-31
RU2016142225A (ru) 2018-12-18
US20220010024A1 (en) 2022-01-13
EP2429582A4 (en) 2013-01-23
KR20160005143A (ko) 2016-01-13
US20160208010A1 (en) 2016-07-21
KR20140102764A (ko) 2014-08-22
SG176060A1 (en) 2011-12-29
US20120100152A1 (en) 2012-04-26
CA2939492C (en) 2019-03-19
TW201043694A (en) 2010-12-16
MY160126A (en) 2017-02-28
IL216141A0 (en) 2012-01-31
JP2016093194A (ja) 2016-05-26
CA2939492A1 (en) 2010-11-18
ZA201108077B (en) 2013-01-30
TWI614267B (zh) 2018-02-11
WO2010132659A2 (en) 2010-11-18
CN104231084B (zh) 2019-04-23
IL216141B (en) 2018-11-29
EP2998405A1 (en) 2016-03-23
MX2011012047A (es) 2011-12-14
US8617554B2 (en) 2013-12-31
HK1205152A1 (en) 2015-12-11
WO2010132659A3 (en) 2011-01-06
AR076770A1 (es) 2011-07-06
RU2011150516A (ru) 2013-06-20
JP2012526558A (ja) 2012-11-01
CN110016081A (zh) 2019-07-16
AU2010249003B2 (en) 2015-08-20
US20140341910A1 (en) 2014-11-20
EP2998405B1 (en) 2019-12-11
NZ621170A (en) 2015-08-28
TWI529247B (zh) 2016-04-11
HK1222682A1 (en) 2017-07-07
JP2018029624A (ja) 2018-03-01
CA2761800C (en) 2016-09-27
NZ596384A (en) 2014-03-28
TW201636367A (zh) 2016-10-16
CA2761800A1 (en) 2010-11-18
JP2014195474A (ja) 2014-10-16
AU2010249003A1 (en) 2011-11-03
US11945874B2 (en) 2024-04-02
BRPI1013085A2 (pt) 2020-11-03
EP2429582A2 (en) 2012-03-21
CN102459628A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
KR101537840B1 (ko) 항-인간 ｃｄ52 면역글루불린
KR102713355B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
US7981416B2 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency
CN101848999A (zh) 抗-cd20单克隆抗体
AU2017202364B2 (en) Anti-human CD52 immunoglobulins
HK40031934A (en) Anti-human cd52 immunoglobulins

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170922

Application number text: 1020167022759

Filing date: 20160819

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171020

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20171218

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180724

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20171218

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I